29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This trial found no benefit of 24-month multidomain intervention with focus on improvement in lifestyle and vascular risk factors on the incidence of poststroke cognitive decline in comparison with standard stroke care. 1 key finding →
Participants: 101 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Considering several covariates together allowed the identification of responders. 2 key findings →
Participants: 186 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00257712. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. 3 key findings →
Design: clinical trial Participants: 421 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo. 2 key findings →
Participants: 67 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Encoding-task fMRI was successfully implemented in a single-site, 24-week, AD randomized controlled trial. 2 key findings →
Design: randomized controlled trial Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study found no effect of ongoing BDZR use on ADAS-Cog scores in those with mild to moderate AD over 18 months. 5 key findings →
Design: randomized controlled trial Participants: 448 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In community-dwelling older persons, the combination of a long-term lifestyle MI and omega-3 supplementation did not reduce frailty level or incidence. 3 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Selection criteria All unconfounded trials specified as randomized in which treatment with piracetam was administered for more than a day and compared with placebo in patients with dementia of Alzheimer type, vascular dementia,or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease sufferers have been found to have a lack of the enzyme responsible for converting choline into acetylcholine within the brain. 5 key findings →
Design: randomized controlled trial Participants: 265 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). 4 key findings →
Participants: 129 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our pilot studies (National Institutes of Health [NIH] stage 1A) have shown that MHB is feasible, acceptable, and associated with improvement in lifestyle behavior and cognitive outcomes. 4 key findings →
Design: randomized controlled trial Participants: 225 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Online education involving a celebrity may be an effective strategy for educating college students about AD risk reduction strategies. 1 key finding →
Design: randomized controlled trial Participants: 721 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A brief DMA combined with plasma pTau217 identifies a subset of cognitively unimpaired, amyloid-positive older adults at highest risk for cognitive and biomarker progression. 2 key findings →
Participants: 818 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant. 1 key finding →
Participants: 653 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The ADL benefits in AD patients treated with donepezil were associated with less caregiving time and lower levels of caregiver stress. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although cholinesterase inhibitors have produced statistically significant treatment effects, their clinical meaningfulness in Alzheimer's disease is disputed. 4 key findings →
Design: randomized controlled trial Participants: 159 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Immunization against amyloid-beta has been suggested as a possible preventive or therapeutic treatment for Alzheimer's disease. 1 key finding →
Design: longitudinal study Participants: 365 Evidence: moderate
Full summary, score breakdown and related studies → Original source
ARIA-E is rare in cognitively unimpaired Aβ+ and Aβ- populations prior to anti-amyloid drug intervention. 4 key findings →
Design: cross-sectional Participants: 1,250 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. 1 key finding →
Design: open-label trial Evidence: low
Full summary, score breakdown and related studies → Original source
Memantine (Ebixa, Axura, Namenda, Akatinol) is a moderate-affinity, uncompetitive, voltage-dependent, NMDA-receptor antagonist with fast on/off kinetics that inhibits excessive calcium influx induced by chronic overstimulation of the NMDA receptor. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Twelve studies were included in the final analysis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study investigated the association of statin use with sepsis risk in patients with dementia. 1 key finding →
Design: cohort study Participants: 308 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Donanemab treatment significantly slowed clinical progression at 76w and had a safety profile consistent with earlier studies. 5 key findings →
Participants: 1,182 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →